| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Bankruptcy > Filing Bankruptcy in Federal Courts |
|
Advice You - Filing Bankruptcy in Federal Courts
One cannot file for bankruptcy through US state courts, since exclusive jurisdiction is ve According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product sted with Federal courts. The court charges a certain fee at the time of filing, depending ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in on which category of bankruptcy is being filed for. Specifically, a court fee for filing f lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. or Chapter 7 bankruptcy is $274, $1,039 for Chapter 11, $239 for Chapter 12 and $139 for C here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe apter 13. The charges vary for single individuals and married couples and can be paid in i d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro nstallments over a period of 120 days. The Federal Rules of Bankruptcy Procedure has a fo ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc mal procedure for filing, which is further specific to the bankruptcy laws of each judicia easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi l district. The US has 90 formal districts in which bankruptcy can be filed for, and the o nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically erall power over these is vested with the United States bankruptcy judge. Someone filing f and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ or Chapter 7 bankruptcy will usually have no direct dealings with a judge, while someone f ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ling for Chapter 13 bankruptcy will appear before a judge at the official plan confirmatio ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a n. The applicant will, however, attend the 341 meeting (so called because it is required dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod y section 341 of the Bankruptcy Code). In this meeting, the person applying for bankruptcy cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin meets with all creditors involved and answers questions pertaining to assets, property, e tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen c. The form that needs to be filled out for filing bankruptcy encompasses something like t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel 20 pages. It is this extensive because the applicant needs to provide the court with compl ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust te information regarding income and expenses, assets and liabilities and all financial tra y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products nsactions in the immediate past. The form is available with most legal stationers and cost . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de around $20. The bankruptcy petition must be filed in the applicable district’s local ban elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip kruptcy court, along with documentation pertaining to previous applications for bankruptcy tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:CeMAP Training in a Higher Interest Rate Market Make Money Online Fast - Can You Really Make Money Online Fast?
|